Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Collaborator: Hoffmann-La Roche
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Behcet's Disease fulfilling the new International Criteria for Behcet's Disease

• Having active ocular lesions (posterior and/or retinal vasculitis)

• Resistant to cytotoxic drugs + prednisolone 0.5 mg/kg

Exclusion Criteria:

• Visual acuity less than 1/10 on Snellen chart

• Antecedent of allergic reaction to any component of the therapeutic regimen